Celldex Therapeutics Faces Trading Halt After Disappointing Trial Results

Celldex Therapeutics (NASDAQ: CLDX) faces a trading halt after a 21% drop in shares due to disappointing Phase 2 study results for Barzolvolimab, a treatment for Chronic Spontaneous Urticaria. This volatility highlights the risks in biotech investments and the importance of staying informed amid broader market uncertainties.